Summary of major results with descriptive and inferential statistics
| Group | N | Baseline | Maximum | % | Days | F | df | Figures |
|---|---|---|---|---|---|---|---|---|
| No change | ||||||||
| 5 d binocular deprivation | 5 | 0.388 ± 0.0009 | 0.386 ± 0.0018 | 0 | 0 | 1.14 | 4, 6 | 3D |
| 5 d MD + ipsilateral muscimol | 5 | 0.392 ± 0.0004 | 0.390 ± 0.0012 | 0 | 0 | 1 | 5, 31 | 4B |
| Small enhancement (∼10%) | ||||||||
| Enucleation | 4 | 0.393 ± 0.0005 | 0.434 ± 0.0017 | 10 | NA | 115 | 3, 15 | 3E |
| 5 d MD + bilateral lesions | 6 | 0.388 ± 0.0021 | 0.430 ± 0.0009 | 11 | 0 | 130 | 5, 14 | 4A |
| Intermediate enhancement (∼28%); no persistence | ||||||||
| 5 d MD + without testing | 6 | 0.387 ± 0.0021 | 0.497 ± 0.0000 | 29 | 0 | 2017 | 4, 7 | 3A |
| 10 d MD + without testing | 6 | 0.388 ± 0.0015 | 0.495 ± 0.0006 | 28 | 0 | 4469 | 5, 7 | 3B |
| Maximal enhancement (∼37%); no persistence | ||||||||
| 3 d MD (first) | 5 | 0.389 ± 0.0009 | 0.530 ± 0.0007 | 36 | 0 | 14769 | 5, 10 | 5A, 5D |
| 3 d MD (second) | 5 | 0.388 ± 0.0009 | 0.527 ± 0.0015 | 36 | 0 | 4841 | 4, 10 | 6A, 6D |
| 5 d MD + contralateral muscimol | 6 | 0.385 ± 0.0006 | 0.531 ± 0.0018 | 37 | 0 | 2185 | 5, 31 | 4C |
| Maximal enhancement (∼37%); with short persistence | ||||||||
| 5 d MD (first) | 5 | 0.395 ± 0.0014 | 0.5372 ± 0.0007 | 36 | 5 | 1018 | 4, 19 | 1 |
| 5 d MD (first) | 7 | 0.396 ± 0.0012 | 0.5463 ± 0.0021 | 38 | 6 | 607 | 6, 21 | 1, 5B, 5D |
| 5 d MD (ipsilateral Elvax control) | 3 | 0.387 ± 0.0030 | 0.5310 ± 0.0015 | 37 | 6 | 968 | 2, 15 | 4B |
| 5 d MD (contralateral Elvax control) | 2 | 0.387 ± 0.0023 | 0.5268 ± 0.0011 | 36 | 6 | 6907 | 1, 15 | 4C |
| 5 d MD (after ipsilateral muscimol) | 5 | 0.390 ± 0.0006 | 0.5128 ± 0.0016 | 31 | 7 | 1117 | 4, 16 | 4B |
| 5 d MD (after contralateral muscimol) | 6 | 0.392 ± 0.0005 | 0.5345 ± 0.0015 | 36 | 7 | 1215 | 5, 16 | 4C |
| Maximal enhancement (∼37%); with extended persistence | ||||||||
| 5 d MD + ×2 testing | 5 | 0.389 ± 0.0013 | 0.535 ± 0.0012 | 37 | 8 | 1589 | 4, 25 | 3C, 5D |
| 10 d MD (first) | 5 | 0.385 ± 0.0037 | 0.530 ± 0.0016 | 38 | 11 | 1764 | 4, 30 | 5C, 5D, 6E, 6F |
| 5 d MD (second) | 7 | 0.396 ± 0.0021 | 0.547 ± 0.0021 | 38 | 31 | 1541 | 6, 30 | 6B, 6D, 6F |
| 10 d MD (second) | 5 | 0.389 ± 0.0009 | 0.538 ± 0.0007 | 38 | 36 | 6639 | 4, 35 | 6C, 6D, 6E |
| 5 d MD (second after 6 months) | 5 | 0.397 ± 0.0016 | 0.548 ± 0.0026 | 38 | 66 | 1402 | 4, 31 | NA |
| 10 d MD (third) | 3 | 0.389 ± 0.0024 | 0.532 ± 0.0007 | 37 | 85 | 346 | 2, 39 | 6E |
Groups are listed (left column) and arranged (subheadings) according to experimental effects. The number of animals in a group (N), the baseline spatial frequency sensitivity with SEM (Baseline), the maximum sensitivity over the course of the experiment with SEM (Maximum), the percentage change between baseline and maximum sensitivity (%), the number of days enhanced sensitivity persists above baseline after MD (Days), F values of repeated-measures ANOVAs for the group (F), degrees of freedom of the analysis (df), and references to figure number and panel of the experiment (Figures) are listed for each group in columns.